Study of posaconazole with immunotherapy and chemo for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests if adding posaconazole (an antifungal drug) to standard immunotherapy and chemotherapy before breast cancer surgery works better than just the standard treatment. It is for people with newly diagnosed, early-stage triple-negative breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have just been diagnosed with triple-negative breast cancer for the first time.
- Your cancer is stage II or III (not stage I or IV).
- You are healthy enough for daily activities (ECOG score 0 or 1).
- You have not had breast cancer before or received radiation or systemic therapy for another cancer.
- You do not have an immune system disease or connective tissue disease, and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy (camrelizumab), an anti-fibrotic drug (pirfenidone), and standard chemotherapy for people with advanced triple-negative breast cancer that has not gotten worse after initial treatment. The goal is to see if this mix works better than chemo alone.
This trial tests a new combination of targeted chemotherapy (sacituzumab govitecan) with immunotherapy (pembrolizumab) against standard chemotherapy for people with triple-negative breast cancer that has not spread. It is for those who have already started a specific chemotherapy and immunotherapy regimen and may qualify if their cancer is stage II or III.
This trial tests a combination of chemotherapy, the immunotherapy drug pembrolizumab, and low or high-dose radiation before surgery for people with triple-negative breast cancer that has spread to the lymph nodes. The goal is to see if this approach can improve treatment outcomes.
This trial tests a combination of an immunotherapy drug (camrelizumab), a chemotherapy drug (nab-paclitaxel), and an allergy medicine (levocetirizine) for people with triple negative breast cancer that has spread or come back. The goal is to see if adding the allergy medicine helps the treatment work better.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) before surgery can improve outcomes for people with early-stage triple-negative breast cancer. It aims to shrink the tumor and increase the chance of a complete response.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.